Full Year 2025 RTW Biotech Opportunities Ltd Earnings Call Transcript
Key Points
- RTW Biotech Opportunities Ltd (LSE:RTW) reported a 36% growth in NAV per share, outperforming the NASDAQ Biotech Index and its AIC sector peers.
- The company has delivered a 136% NAV return since IPO, significantly outperforming major biotech indices.
- RTW Biotech Opportunities Ltd has a strong global presence with offices in New York, London, and Shanghai, and a team of 80 professionals.
- The company has a robust investment strategy focusing on full lifecycle investing, from early development to commercialization.
- RTW Biotech Opportunities Ltd's flagship funds have generated a 23% annualized net return over more than 15 years.
- The biotech sector faced a four-year bear market, impacting overall performance despite recent recovery.
- FDA leadership changes have introduced uncertainty, particularly affecting rare disease and gene therapy approvals.
- The IPO market for biotech remained largely closed last year, with only six IPOs, although there are signs of recovery.
- The geopolitical situation, such as the Iran war, poses risks to the pace of IPOs and market stability.
- Despite strong performance, the company acknowledges the need for more share buybacks to address NAV discounts.
(video playing)
Good morning and welcome to the RTW Biotech Opportunities Limited investor presentation. Throughout this recorded meeting, investors will be in lesson only mode. Questions can be submitted at any time by the Q&A tab situated on the right-hand corner. of your screen.
Simply just type in your question and press send. Company may not be in a position to answer every question received during the meeting. itself. However, the company can review all questions submitted today and publish responses where.
it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Oliver Kenyon, Senior Director of Business and Corporate. Development. Good morning.
Thank you. Good morning and thank you for joining us for this presentation of the annual results. for RTW Biotech Opportunities at the end of December 2025.
I'm Oliver Kenyon, Director of Business Development at RTW
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
